ArticleComputational and structural biotechnology journal2013
The innovative medicines initiative: a public private partnership model to foster drug discovery.
Article in Computational and structural biotechnology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Designing interdisciplinary education in digital public health: a position paper.Frontiers in public health · 2026Article
- Challenges and opportunities of acquiring cortical recordings for chronic adaptive deep brain stimulation.Nature biomedical engineering · 2025Review
- Review
- Article
- Predictive validity in drug discovery: what it is, why it matters and how to improve it.Nature reviews. Drug discovery · 2022Review
- Selection of data sets for FAIRification in drug discovery and development: Which, why, and how?Drug discovery today · 2022Review
- On drug discovery against infectious diseases and academic medicinal chemistry contributions.Beilstein journal of organic chemistry · 2022Article
- Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.Pharmaceutical medicine · 2019Review
- Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?Journal of translational medicine · 2018Review
- Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.Drug safety · 2017Article
- The Proteomics of Intrathecal Analgesic agents for Chronic Pain.Current neuropharmacology · 2017Review
- StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium.Stem cell reviews and reports · 2015Review
- Personalized medicine in hematology - A landmark from bench to bed.Computational and structural biotechnology journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Innovative Medicines Initiative (IMI) is a large-scale public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavours between large pharmaceutical companies and other key actors in the health-care ecosystem, i.e., academic institutions, small and medium enterprises, patients, and regulatory authorities. Currently there are more than 40 IMI projects covering the whole value chain of pharmaceutical R&D, but with a strong focus on drug discovery, as an ideal arena where the PPP concept of pre-competitive collaboration can rapidly deliver results. This article review recent achievements of the IMI consortia of relevance to drug discovery, providing proof-of-concept evidence for the efficiency of this new model of collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.